Brief: Bioxyne Reports Full Year FY2026 Revenue Guidance Of A$65 Million - A$75 Million
29/08/2025 03:50
Aug 29 (Reuters) - Bioxyne Ltd BXN.AX: FULL YEAR FY2026 REVENUE GUIDANCE OF A$65 MILLION - A$75 MILLION FULL YEAR FY2026 EBITDA GUIDANCE OF A$11.5 MILLION - A$13.5 MILLION Further company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BLS Pharmaceuticals
See all newsBrief: BLS Pharmaceuticals Posts Q1 FY27 Revenue A$26.7M
Brief: BLS Pharmaceuticals Reports Record Q1 FY27 Revenue Of A$26.7 Million
Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results
Brief: BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26%
Brief: BLS Pharmaceuticals Posts FY Net Profit After Tax Of A$15.4 MLN